retatrutide phase 2 trial obesity triple agonist hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide (LY-3437943) Market Analysis, 2033:
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17



























